Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene

Neuroscience Letters

Volumn 500, Issue 2, 2011, Pages 95-98

  Pereira, Marcela ^a   Martynhak, Bruno Jacson ^a   Baretta, Irinéia Paulina ^a,b   Correia, Diego ^a   Siba, Isadora Pozzetti ^a   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSIDADE PARANAENSE   (Brazil)

Author keywords

Antiestrogenic; Bipolar disorder; Locomotor activity; Methylphenidate

Indexed keywords

ACETOFLUX; CLOMIFENE CITRATE; MEDROXYPROGESTERONE; METHYLPHENIDATE; PROTEIN KINASE C; TAMOXIFEN; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; MALE; MANIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY; TREATMENT DURATION;

ANIMALS; ANTIMANIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLOMIPHENE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; MALE; MEDROXYPROGESTERONE; METHYLPHENIDATE; MICE; MOTOR ACTIVITY; PROTEIN KINASE C; TAMOXIFEN;

EID: 79960453372     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.06.012     Document Type: Article

References (29)

1. Ali S.M., Ahmad A., Shahabuddin S., Ahmad M.U., Sheikh S., Ahmad I. Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder. Bioorg. Med. Chem. Lett. 2010, 20:2665-2667.
2. F. Armani, M.L. Andersen, R. Andreatini, R. Frussa-Filho, S. Tufik, J.C.F. Galduróz, Low-dose tamoxifen as an adjunct to reduce lithium therapeutic dose requirement in a mice model of mania induced by paradoxical sleep deprivation, CNS Neurosci. Ther., doi:10.1111/j.1755-5949.2010.00224.x.
3. Barbosa F.J., Hesse B., de Almeida R.B., Baretta I.P., Boerngen-Lacerda R., Andreatini R. Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania. Pharmacol. Rep. 2011, 63:64-70.
4. Bebchuk J.M., Arfken C.L., Dolan-Manji S., Murphy J., Hasanak K., Manji H.K. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 2000, 57:95-97.
5. Chouinard G., Steinberg S., Steiner W. Estrogen-progesterone combination: another mood stabilizer?. Am. J. Psychiatry 1987, 144:826.
6. Diaz Granados N., Zarate C.A. A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr. Psychiatry Rep. 2008, 10:510-519.
7. Einat H. Modeling facets of mania: new directions related to the notion of endophenotypes. J. Psychopharmacol. 2006, 20:714-722.
8. Einat H., Yuan P., Szabo S.T., Dogra S., Manji H.K. Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats: implications for the development of novel therapeutics for bipolar disorder. Neuropsychobiology 2007, 55:123-131.
9. Frey B.N., Andreazza A.C., Ceresér K.M., Martins M.R., Valvassori S.S., Réus G.Z., Quevedo J., Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. 2006, 79:281-286.
10. Gitlin M. Treatment-resistant bipolar disorder. Mol. Psychiatry 2006, 11:227-240.
11. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field in two inbred strains of mice. Behav. Brain Res. 2001, 118:95-105.
12. Hahn C.G., Friedman E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord. 1999, 1:81-86.
13. Hahn C.G., Umapathy H.Y., Wang R., Koneru D.F., Levinson E., Friedman Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J. Psychiatr. Res. 2005, 39:355-363.
14. Huang M.C., Wang Y.B., Chan C.H. Estrogen-progesterone combination for treatment-refractory post-partum mania. Psychiatry Clin. Neurosci. 2008, 62:126.
15. Irwin R.W., Yao J., Ahmed S.S., Hamilton R.T., Cadenas E., Brinton R.D. Medroxyprogesterone acetate antagonizes estrogen up-regulation of brain mitochondrial function. Endocrinology 2011, 152:556-567.
16. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Häggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997, 138:863-870.
17. Kulkarni J., Garland K.A., Scaffidi A., Headey A., Anderson R., Castella A., Fitzgerald P., Davis S.R. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006, 31:543-547.
18. Kurosawa T., Hiroi H., Momoeda M., Inoue S., Taketani Y. Clomiphene citrate elicits estrogen agonistic/antagonistic effects differentially via estrogen receptors α and β. Endocr. J. 2010, 57:517-521.
19. Manji H.K., Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry 2002, 7(Suppl. 1):S46-S56.
20. Manji H.K., Lenox R.H. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry 1999, 46:1328-1351.
21. Mhyre A.J., Dorsa D.M. Estrogen activates rapid signaling in the brain: role of estrogen receptor α and estrogen receptor β in neurons and glia. Neuroscience 2006, 138:851-858.
22. Moretti M., Valvassori S.S., Steckert A.V., Rochi N., Benedet J., Scaini G., Kapczinski F., Streck E.L., Zugno A.I., Quevedo J. Tamoxifen effects on respiratory chain complexes and creatine kinase activities in an animal model of mania. Pharmacol. Biochem. Behav. 2011, 98:304-310.
23. Nicoletti F., Speciale C., Sortino M.A., Summa G., Caruso G., Patti F., Canonico P.L. Comparative effects of estradiol benzoate, the antiestrogen clomiphene citrate, and the progestin medroxyprogesterone acetate on kainic acid-induced seizures in male and female rats. Epilepsia 1985, 26:252-257.
24. Nierenberg A.A. A critical appraisal of treatments for bipolar disorder. Prim. Care Companion J. Clin. Psychiatry 2010, 12(Suppl. 1):23-29.
25. Sabioni P., Baretta I.P., Ninomiya E.M., Gustafson L., Rodrigues A.L., Andreatini R. The antimanic-like effect of tamoxifen: behavioural comparison with other PKC-inhibiting and antiestrogenic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1927-1931.
26. Tandon P., Gupta M.L., Barthwal J.P., Gupta T.K., Parmar S.S., Bhargava K.P. Role of monoamine oxidase-B in medroxyprogesterone acetate (17-acetoxy-6 α-methyl-4-pregnene-3, 20-dione) induced changes in brain dopamine levels of rats. Steroids 1983, 42:231-239.
27. Wang H., Isaksson E., Von Schoultz B., Cline J.M., Sahlin L. The effect of long-term treatment with steroid hormones or tamoxifen on oestrogen receptors (α and β) in the endometrium of ovariectomized cynomolgus macaques. J. Endocrinol. 2002, 175:673-681.
28. Yildiz A., Guleryuz S., Ankerst D.P., Ongür D., Renshaw P.F. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry 2008, 65:255-263.
29. Zarate C.A., Singh J.B., Carlson P.J., Quiroz J., Jolkovsky L., Luckenbaugh D.A., Manji H.K. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord. 2007, 9:561-570.